Ventyx Won’t Pursue Psoriasis Further Despite Phase II Success

 
• By Joseph Haas
Psoriasis
Ventyx is abandoning psoriasis and psoriatic arthritis plans for its TYK2 inhibitor • Source: Shutterstock

More from Strategy

More from Business